Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Neuropharmacology
|
January 17, 2013
Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats
Guy Griebel, Sandra Beeské, Agnès Jacquet, et al.
CNS Drug Reviews
|
May 4, 2005
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders
Claudine Serradeil-Le Gal, Jean Wagnon, Bernard Tonnerre, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 10, 2008
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal
Alexandre Surget, Yingjie Wang, Samuel Leman, et al.
Biological Psychiatry
|
April 15, 2008
Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal
Alexandre Surget, Michael Saxe, Samuel Leman, et al.
Stress (Amsterdam, Netherlands)
|
September 18, 2003
Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals
Claudine Serradeil-Le Gal, Sylvain Derick, Gabrielle Brossard, et al.
Frontiers in Psychiatry
|
November 3, 2025
Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression
Christine Zu Eulenburg, Daniel Gehrlach, Marius Myhsok, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 3, 2005
Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]
Stephanie C Licata, Donna M Platt, James M Cook, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2002
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 22, 2002
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders
Guy Griebel, Jacques Simiand, Régis Steinberg, et al.
Psychopharmacology
|
August 19, 2008
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat
Mark D Black, Geoffrey B Varty, Michal Arad, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Neuropharmacology
|
January 17, 2013
Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats
Guy Griebel, Sandra Beeské, Agnès Jacquet, et al.
CNS Drug Reviews
|
May 4, 2005
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders
Claudine Serradeil-Le Gal, Jean Wagnon, Bernard Tonnerre, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 10, 2008
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal
Alexandre Surget, Yingjie Wang, Samuel Leman, et al.
Biological Psychiatry
|
April 15, 2008
Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal
Alexandre Surget, Michael Saxe, Samuel Leman, et al.
Stress (Amsterdam, Netherlands)
|
September 18, 2003
Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals
Claudine Serradeil-Le Gal, Sylvain Derick, Gabrielle Brossard, et al.
Frontiers in Psychiatry
|
November 3, 2025
Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression
Christine Zu Eulenburg, Daniel Gehrlach, Marius Myhsok, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 3, 2005
Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]
Stephanie C Licata, Donna M Platt, James M Cook, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2002
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 22, 2002
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders
Guy Griebel, Jacques Simiand, Régis Steinberg, et al.
Psychopharmacology
|
August 19, 2008
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat
Mark D Black, Geoffrey B Varty, Michal Arad, et al.
Page
of 7